Document Type
Article
Publication Date
7-2-2024
Original Citation
Meric-Bernstam F,
Lloyd M,
Koc S,
Evrard Y,
McShane L,
Lewis M,
Evans K,
Li D,
Rubinstein L,
Welm A,
Dean D,
Srivastava A,
Grover J,
Ha M,
Chen H,
Huang X,
Varadarajan K,
Wang J,
Roth J,
Welm B,
Govinden R,
Ding L,
Kaochar S,
Mitsiades N,
Carvajal-Carmona L,
Herylyn M,
Davies M,
Shapiro G,
Fields R,
Trevino J,
Harrell J,
,
Doroshow J,
Chuang J,
Moscow J.
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. 2024;23(7):924-38.
Keywords
JGM, JMG, Humans, Animals, Xenograft Model Antitumor Assays, Neoplasms, National Cancer Institute (U.S.), United States, Mice, Antineoplastic Agents, Consensus
JAX Source
Mol Cancer Ther. 2024;23(7):924-38.
ISSN
1538-8514
PMID
38641411
DOI
https://doi.org/10.1158/1535-7163.Mct-23-0471
Grant
This work was supported in part by NCI PDX Development and Trial Centers grants U54CA224065, U54CA224083, U54CA224076, U54CA224070, CPRIT RP170691, and 4UM1CA186688; NIH Clinical Translational Science Award 1UL1TR003167 and the NIH/NCI under award numbers P30CA016672 and P30CA125123
Abstract
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.